Act Two Investors LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,710 shares of the medical research company's stock, valued at approximately $3,364,000. Thermo Fisher Scientific makes up approximately 0.7% of Act Two Investors LLC's portfolio, making the stock its 24th biggest holding.
Several other institutional investors have also modified their holdings of the business. Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $46,340,000. Danske Bank A S bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $120,783,000. Diversify Advisory Services LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter worth $1,099,000. Gables Capital Management Inc. bought a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $1,668,000. Finally, Wealthfront Advisers LLC acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth about $12,952,000. Institutional investors own 89.23% of the company's stock.
Thermo Fisher Scientific Stock Performance
Shares of NYSE TMO opened at $614.32 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The stock has a 50 day moving average of $536.26 and a 200-day moving average of $508.51. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $227.14 billion, a P/E ratio of 33.05, a P/E/G ratio of 2.40 and a beta of 0.85.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter last year, the firm posted $4.28 EPS. The company's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.
Thermo Fisher Scientific Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.
Insider Activity at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 5,850 shares of the company's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the transaction, the vice president directly owned 14,784 shares of the company's stock, valued at $8,574,720. This represents a 28.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 52,053 shares of company stock valued at $30,643,589. Insiders own 0.33% of the company's stock.
Analysts Set New Price Targets
TMO has been the topic of a number of recent research reports. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective on the stock. Weiss Ratings raised shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, July 14th. Barclays upped their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Stifel Nicolaus set a $650.00 price target on Thermo Fisher Scientific in a research note on Wednesday, August 5th. Finally, Piper Sandler boosted their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $619.41.
Get Our Latest Research Report on TMO
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
